A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period

Name: A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period
Creator: Vivli
Published: 2025-12-08 23:14:34
License: 暂无描述

DataCite Commons2025-12-08 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/00004505/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

提供机构：

Vivli

创建时间：

2019-09-09